ORUKA Trademark

Trademark Overview


On Monday, July 15, 2024, a trademark application was filed for ORUKA with the United States Patent and Trademark Office. The USPTO has given the ORUKA trademark a serial number of 98649557. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Wednesday, May 27, 2026. This trademark is owned by Oruka Therapeutics, Inc.. The ORUKA trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Biochemical preparations for scientific purposes, namely, in vitro scientific or research use; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use

Biologics in the nature of pharmaceutical preparations for treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications; Antibodies for medical purposes, namely, for treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications; Therapeutic pharmaceutical for the treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications

Biotechnology research related to antibodies and therapies for treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications

General Information


Serial Number98649557
Word MarkORUKA
Filing DateMonday, July 15, 2024
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateWednesday, May 27, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 22, 2025

Trademark Statements


Goods and ServicesBiochemical preparations for scientific purposes, namely, in vitro scientific or research use; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use
Goods and ServicesBiologics in the nature of pharmaceutical preparations for treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications; Antibodies for medical purposes, namely, for treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications; Therapeutic pharmaceutical for the treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications
Goods and ServicesBiotechnology research related to antibodies and therapies for treatment of chronic skin diseases such as plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateMonday, July 15, 2024
Primary Code001
First Use Anywhere DateMonday, December 1, 2025
First Use In Commerce DateMonday, December 1, 2025

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 15, 2024
Primary Code005
First Use Anywhere DateMonday, December 1, 2025
First Use In Commerce DateMonday, December 1, 2025

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, July 15, 2024
Primary Code042
First Use Anywhere DateMonday, December 1, 2025
First Use In Commerce DateMonday, December 1, 2025

Trademark Owner History


Party NameOruka Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025
US

Party NameOruka Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025
US

Trademark Events


Event DateEvent Description
Monday, July 15, 2024NEW APPLICATION ENTERED
Monday, July 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 31, 2024ASSIGNED TO EXAMINER
Tuesday, January 14, 2025NON-FINAL ACTION WRITTEN
Tuesday, January 14, 2025NON-FINAL ACTION E-MAILED
Tuesday, January 14, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 26, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 26, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 26, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 27, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 16, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 22, 2025PUBLISHED FOR OPPOSITION
Tuesday, April 22, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 17, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, December 12, 2025SOU TEAS EXTENSION RECEIVED
Friday, December 12, 2025SOU EXTENSION 1 FILED
Friday, December 12, 2025SOU EXTENSION 1 GRANTED
Saturday, December 13, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 17, 2025TEAS STATEMENT OF USE RECEIVED
Wednesday, December 17, 2025USE AMENDMENT FILED
Tuesday, May 5, 2026STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 27, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 27, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED